FDAnews
www.fdanews.com/articles/198411-fda-clears-rlf-100-for-covid-19-trial
FDA clears text

FDA Clears RLF-100 for COVID-19 Trial

August 7, 2020

The FDA has granted Relief Therapeutics and NeuroRx approval for a phase 2/3 trial of inhaled RLF-100 (aviptadil) for the prevention of respiratory failure in patients with moderate to severe COVID-19 infections.

Aviptadil is a synthetic form of a natural peptide that has been shown to block replication of the SARS-CoV-2 coronavirus in human lung cells and immune cells.

The first phase of the trial will enroll patients hospitalized for severe COVID-19 who do not have respiratory failure. If early results are promising, the trial will be expanded to include patients at home with mild and moderate COVID-19.

View today's stories